The corporations on our annual list of the world's 500 largest companies combined to generate $41.7 trillion in revenue over the past year.

Fortune Global 500

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

Fortune 500

The 300 companies on this year’s list brought in over $12.6 trillion in revenue for the latest 12 months, with the median revenue figure at $22 billion.

America's Most Innovative Companies

Leaders in all industries rely more than ever on Big Tech—and appreciate the giants that deliver, at scale, without drama.

World's Most Admired Companies

The corporations on our annual list posted aggregate revenues of $41 trillion for the second year in a row.

Industries included in the sector are insurance and managed care, medical products and facilities, pharmacy services, and pharmaceutical companies.

Fortune Sector Leaders: Health Care

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

The 26th edition of the list shows how much esteem Big Tech giants command among other business leaders.

The corporations on our annual list of the world’s largest companies delivered a record $41 trillion in aggregate revenues.

The 300 companies on this list are transforming industries from the inside out.

The Fortune 500, in its 69th year in 2023, ranks the biggest U.S. companies by revenue.

This year’s Fortune 500 marks the 68th running of the list.

This year’s Fortune 500 marks the 67th running of the list.

The health care company focuses on reducing the cost and improving the quality of health insurance, as well as insuring clients through programs like Medicare and Medicaid. Molina Healthcare offers Medicaid plans in 18 states.

This year's Fortune 500 marks the 66th running of the list.

F500-2020-193-web_Molina-Center

Molina Healthcare provides health care services to low-income families and individuals who receive care via programs like Medicare and Medicaid in a variety of states and Puerto Rico.

This year's Fortune 500 marks the 65th running of the list.

This year's Fortune 500 marks the 64th running of the list.

This year's Fortune 500 marks the 63rd running of the list.

Everybody loves an up-and-comer: 2017's top three-year performers in revenues, profits, and stock returns.

100 Fastest-Growing Companies

This year's Fortune 500 marks the 62nd running of the list.

Too fast to be stopped: 2016's top three-year performers in revenue, profits, and stock returns.

This year's Fortune 500 marks the 61st running of the list. Wal-Mart claims the top spot again. See who made the list.

This year's Fastest-Growing Companies marks the 19th running of the list. In our annual list of public companies with the most stellar three-year profit, revenue, and stock growth, Facebook makes its first appearance.

Wal-Mart stayed on top as its sales crept closer to half-a-trillion dollars. Apple moved into the top five. And UnitedHealth Group continued its steady climb. 

Fastest-growing Companies

Headquarters

Industry

Sector

Current Streak

Years on List

Website

Revenue, Net Income

Revenue past four quarters ($M)

Net Income past four quarters ($M)

Growth Rates And Ranks

Revenue 3 Yr Growth Rank

Revenue 3 Yr Annual Growth Rate

EPS 3 Yr Growth Rank

EPS 3 Yr Annual Growth Rate

Total Return 3 Yr Rank

Total Return 3 Yr Annual Rate (Through June 28, 2024)

Beat S&P 500 3 Yr Return (10%)

Estimated P/E Ratio

Current All-Star Rank

Previous All-Star Rank

Industry Rank

Previous Industry Rank

Overall Score

Innovation

People Management

Use of Corporate Assets

Social Responsibility

Quality of Management

Financial Soundness

Long-Term Investment Value

Quality of Products/Services

Global Competitiveness

Culture rank

Process rank

Product rank

Years on list

Previous rank

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

Q2 2025

Q1 2025

Q4 2024

Get insights into Molina Healthcare including business profile, stock information, news, and rankings from Fortune.

Molina Healthcare (MOH): Company Profile, Stock Price, News, Rankings

legacy

Molina Healthcare

molina healthcare

Good day, and welcome to the Molina Healthcare First Quarter twenty twenty five Earnings Conference Call. All participants will be in listen only mode. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded. I would now like to turn the conference over to Jeffrey Guyer.

Good morning, and welcome to Molina Healthcare's first quarter twenty twenty five earnings call. Joining me today are Molina's President and CEO, Joe Zabretsky and our CFO, Mark Keim. A press release announcing our first quarter twenty twenty five earnings was distributed after the market closed yesterday and is available on our Investor Relations website. Shortly after the conclusion of this call, a replay will be available for thirty days. The numbers to access the replay are in the earnings release.

For those of you who listen to the rebroadcast of this presentation, we remind you that all of the remarks are made as of today, Thursday, 04/24/2025, and have not been updated subsequent to the initial earnings call. On this call, we will refer to certain non GAAP measures. A reconciliation of these measures with the most directly comparable GAAP measures can be found in the first quarter twenty twenty five earnings release. During the call, we will be making certain forward looking statements, including, but not limited to, statements regarding our 2025 guidance, the estimated amount of our embedded earnings power and future earnings realization, expected Medicaid rate adjustments and updates, our projected MCR, organic Medicaid and Marketplace membership growth, our recent RFP awards, our acquisitions and M and A activity, revenue growth related to RFPs and M and A activity, potential Medicaid funding cuts or program changes, and our long term growth strategy. Listeners are cautioned that all of our forward looking statements are subject to certain risks and uncertainties that could cause our actual results to differ materially from our current expectations.

We advise listeners to review the risk factors discussed in our Form 10 ks annual report filed with the SEC as well as our risk factors listed in our Form 10 Q and Form eight ks filings with the SEC. After the completion of our prepared remarks, we will open the call to take your questions. I will now turn the call over to our Chief Executive Officer, Joe Zabretsky. Joe?

Thank you, Jeff, and good morning. Today, I will discuss several topics. Our reported financial results for

quarter, our growth initiatives and the related increase to embedded earnings, and our full year 2025 guidance, which we reaffirm at $42,000,000,000 of premium revenue and at least $24.5 in earnings per share. Let me start with our first quarter performance. Last night, we reported adjusted earnings per share of $6.8 on $10,600,000,000 of premium revenue, supported by strong operating metrics across all lines of business. Our 89.2% consolidated MCR reflects strong medical cost management and an improving rate environment. We produced a 3.9% adjusted pretax margin or 3% after tax, a very strong result.

In Medicaid, the business produced an MCR of 90.3 in the quarter, which was in line with our expectations. As contemplated in our initial guidance, medical costs increased moderately due to continued utilization of LTSS, high cost drugs and behavioral health services, as well as seasonal illnesses, the impacts of which were mostly offset by updates in the new rate cycle. In Medicare, we reported a first quarter MCR of eighty eight point three percent, which was in line with our expectations. Medical cost trend was as expected, and was adequately captured by rates and risk adjustment. Our strategy of leveraging our existing Medicaid footprint to serve high acuity, low income Medicare beneficiaries is working well.

In Marketplace, the first quarter MCR was 81.7% and was higher than expected. This was the result of prior year items related to final risk adjustment and membership reconciliations, as well as a higher new store MCR related to the first quarter results of our Connecticut acquisition. Excluding these items, the normalized MCR was approximately 77.7%, more in line with our expectations. Turning now to our growth initiatives. We continued our successful track record of winning RFPs in the quarter.

In Medicaid, we successfully defended our position in Nevada, as we were awarded a contract to serve Medicaid beneficiaries in the two largest urban areas in the state. In our Medicare dual eligible business, we were awarded a contract in Illinois to provide a fully integrated dual eligible special needs plan. This win completes the full transition of our existing MMP members to an integrated DSNP product in all of our MMP states for 01/01/2026. We project incremental annual premium revenue of approximately $800,000,000 from this new contract and have added $0.50 per share to our embedded earnings. This contract win also moves us closer to achieving our premium revenue target of $46,000,000,000 in 2026 and at least $52,000,000,000 which is the low end of our target range for 2027.

With respect to M and A activity, our acquisition pipeline continues to contain many actionable opportunities, as we remain opportunistic in deploying capital to accretive acquisitions. Embedded earnings have now increased from approximately $7.75 to $8.65 per share. This represents approximately one third of our current EPS and serves to support our target future growth rate. Turning now to our 2025 guidance. Full year 2025 premium revenue guidance remains unchanged at approximately $42,000,000,000 We also reaffirm our full year 2025 adjusted earnings per share guidance of at least $24.5 or 8% year over year growth.

Mark will discuss a few of the changing components within our EPS guidance, a major point of which will be that full year 2025 Medicaid rates are projected to be slightly higher than previously expected, as states reflect recent cost trends in on and off cycle rate updates. Given that known fact, we also increased our outlook for cost trend, reflecting some conservatism at this early point in the year. Our 2025 guidance is a strong foundation off of which to grow and to realize the embedded earnings power of the opportunities we have already secured. Turning now to the political and legislative landscape. In Medicaid, we continue to believe that any changes to the Medicaid program in the near term will be marginal.

The general perception is that Congress and the current administration will implement Medicaid program changes through possible combinations of various funding reduction approaches in order to meet federal spending targets. There are many credible estimates of the potential impact of these various approaches. We continue to believe that any impacts to membership volume or the acuity of the risk pool will be manageable and will not disrupt the earnings trajectory of our business. You are all well aware of the complex legislative process which will ensue over the coming months to reconcile the Senate and House resolutions to a final bill. While we await a definitive legislative framework, we continue to believe that neither side of

the aisle wants to see an increase in the number of uninsured,

a significant reduction in benefits for those relying on government assistance, or the inevitable related impact to providers. In Medicare, we are pleased with the recent CMS final rate notice for Medicare Advantage. In addition, the early read on states promoting the integration of Medicaid and Medicare bodes well for us having a significant Medicaid footprint and a competitive DSNP offering. Finally, in marketplace, we remain confident in the stability of our membership and the outlook for the business, despite the various program integrity initiatives and a final decision on the enhanced subsidies, which would impact Marketplace enrollment in 2026. Any impacts to membership have been contemplated in current year guidance and our future year revenue outlook.

States have also communicated a willingness to allow market participants to update rates for 2026, based on the final resolution of the enhanced subsidies, which would substantially mitigate any related pricing risk. Our first quarter results and reaffirmed full year 2025 guidance reflect our team's disciplined approach to medical cost management in an improving rate environment. Our revenue growth and pre tax margin profiles across all segments remain consistent with our long term targets, and we continue to harvest and replenish embedded earnings. As we take an early look into 2026, we are confident in the process for actuarial soundness and the adequacy of Medicaid rates. In reviewing publicly available information, state by state, we believe that the broad Medicaid market appears to need 200 to 300 basis points of rate in excess of trend to attain some level of program equilibrium.

If rate updates were to be made at that level, recognizing that all market participants obtain the same rate, Molina should be soon returned to performing at 89% or better, perhaps also while paying into the corridors. Our businesses, while not immune to external forces, have been resilient in the face of many uncertainties over the past many years. The redetermination process is behind us. Any legislative changes to the Medicaid program are likely to be marginal, and healthcare is generally less sensitive to economic cycles. Our 2025 earnings and growth profiles are solid, and therefore, we remain very confident in our ability to achieve our 13% to 15% long term earnings per share growth target.

With that, I will turn the call over to Mark for some additional color on the financials. Mark?

and good morning, everyone. Today, I'll discuss additional details on our first quarter performance, the balance sheet and our 2025 guidance. Beginning with our first quarter results. For the quarter, we reported approximately $11,000,000,000 in total revenue and $10,600,000,000 of premium revenue, with adjusted EPS of $6.08 Our first quarter consolidated MCR was 89.2 percent and reflects strong medical cost management and an improving rate environment. In Medicaid, our first quarter reported MCR was 90.3% and in line with our expectations.

As we expected, medical costs increased moderately due to the continued utilization of LTSS, high cost drugs and behavioral health services, as well as seasonal illness. These were largely offset by the first quarter rate cycle, which came in as expected. In Medicare, our first quarter reported MCR was eighty eight point three percent, in line with our expectations. We remain confident in the pricing and benefit adjustments we implemented for 2025. The reported MCR also reflects the improvement related to our decision to exit MAPD in 13 states.

In Marketplace, our first quarter reported MCR was 81.7. The MCR was higher than expected and driven by two prior year items, lower final risk adjustment and member reconciliation adjustments. Also note that the initial new store MCR of Connecticut is as expected running higher than Target early on. Altogether, these three non recurring items accounted for approximately 400 basis points in the quarter. Excluding these items, the normalized marketplace MCR was approximately 77.7 and reflects seasonality that was more in line with our expectations.

Our adjusted G and A ratio for the quarter was 6.8, driven by operating discipline and the continued benefit of operating leverage. Turning to the balance sheet. Our capital foundation remains strong. In the quarter, we harvested approximately $110,000,000 of subsidiary dividends and our parent company cash balance was approximately $190,000,000 at the end of the quarter. Our operating cash flow for the first quarter was 190,000,000 During the quarter, we repurchased approximately 1,700,000.0 shares at a total cost of $500,000,000 Debt at the end of the quarter was two times trailing twelve month EBITDA and our debt to cap ratio was about 47.

We continue to have ample cash and access to capital to fuel our growth initiatives. Days and claims payable at the end of the quarter was 46, lower than normal. While our reserving policies remain consistent, the timing of payments can have quarter to quarter impact on reported reserves as it did this quarter, as we had one additional claim payment cycle. We remain confident in the strength of our reserves. Next, a few comments on our 2025 guidance.

As Joe mentioned, we continue to expect full year premium revenue to be approximately 42,000,000,000 Within that number are a few moving pieces. We expect higher organic growth in our Marketplace and Medicaid segments to offset the midyear loss of our Virginia contract. Recall, we previously guided for this contract to carry through year end, but now we expect our membership to be reallocated to other MCOs mid year. Our full year consolidated MCR is now 88.8%. Within Medicaid, the full year MCR is unchanged at 89.9%.

We are seeing rate increases slightly higher than we had previously expected as our state partners continue to update their actuarial data. These rate increases are offset by our outlook on full year trend, which is now slightly higher and reflects our conservatism at this point in the year. Together, full year rates and trend are both higher by 50 basis points and result in no change to the MCR guidance. Our MCR guidance on Medicare also remains unchanged at 89%. We remain confident in the performance of our Medicare duals and integrated product business.

In Marketplace, we are increasing our full year MCR guidance from 79 to 80, which is the upper end of our long term target range. This 100 basis point increase reflects the unfavorable non recurring impacts in the quarter I discussed earlier. The marketplace MCR trajectory for the rest of the year is largely unchanged from our prior view. We continue to expect this segment to produce mid single digit pretax margins. Effectuation rates remained strong through the first quarter and we are encouraged by early performance of new members added through the open enrollment and special enrollment periods.

Our year end outlook on membership increases by 40,000 to approximately 620,000 members and includes the estimated impact from income verifications and program integrity initiatives. We now expect the full year G and A ratio to be approximately 6.9, better than previously guided by 10 basis points as we continue to drive efficiencies in our operations. We reaffirm our full year EPS guidance of at least $24.5 per share. Within that number are a few moving pieces. Our EPS guidance now includes a $0.40 benefit from share repurchases in the first quarter, zero point '3 zero from higher volumes in our Medicaid and Marketplace segments and $0.30 commensurate with the improved G and A ratio.

These favorable items offset a $0.60 headwind attributable to the higher Marketplace MCR guidance and $0.40 loss from the midyear termination of our Virginia contract. We continue to expect earnings to be evenly distributed throughout the year. Turning to embedded earnings. Our new store embedded earnings are now approximately $8.65 per share, up $0.90 from our prior outlook of 7.75 This increase includes $0.5 from the recent dual contract win in Illinois and an additional $0.40 as we are now recognizing half of the Virginia contract loss in current year guidance rather than next year as previously expected. We expect one third of this new store embedded earnings to emerge in 2026, giving us high confidence in our 13% to 15% long term growth rate.

This concludes our prepared remarks. Operator, we are now ready to take questions.

And the first question comes from Steven Baxter with Wells Fargo. Please go ahead.

Hey, good morning. Just wanted to start on the exchanges. I was hoping first, you could expand what you saw on risk adjustment and also this member reconciliation dynamic. I guess specifically with member reconciliation, what exactly are you describing there and trying to understand better why we should think about that as a non recurring item? Then just thinking about the rest of the year guidance on the MLR lines of the exchanges, obviously, you called out kind of 400 basis points of variance than the first quarter, you're taking up the full year, think by now 100 basis points.

So yes, rest of the year, feels like it's relatively unimpacted. Just trying to understand, you know, kind of the continuing elements of what you saw in the first quarter and how much of that, we need to think about continuing for the rest of the year. Thank you.

Steven, the marketplace story is a very positive one. We did have non recurring items in the first quarter, which elevated the MCR by 400 basis points. I'll kick it to Mark in a minute for more detail. Membership reconciliations, members that were not authorized to be in the plan, we were servicing last year because they were in the membership rules. That was a scrub by CMS to eliminate members who lacked authorization, a one time item.

The other one time item was a true up to twenty twenty four risk adjustment. The final piece, as typical for an acquisition, the MCR will be operating at the inherited MCR, which for Connecticut is in the mid to high 80s. We're still confident in bringing that down to our target to produce the full $1 of earnings accretion that resides in our embedded earnings. The marketplace story is very positive. We're gonna end the year with 620,000 members, mid single digit margins, and still operating within our long term range, albeit an increase from our previous guidance of 79% now to 80%.

Yeah, Joe, I think you got it. Let me just break that down a little further. The 400 basis points is about $40,000,000 and that breaks down pretty much a third, a third, a third on the things that Joe talked about. I'll add a little color to them. On the final prior year risk adjustment, I'm sure you're aware in marketplace, risk adjustment is on a relative absolute basis like Medicare.

So it's right about now that we find relative to the other players exactly how we scored last year. And we were just a little bit less than we thought on risk adjustment when the final numbers came in. These are the weeklies. So that's a non recurring normal function of how we settle up risk adjustment. On member reconciliation, this is not FTR.

This is members that were on the books last year that when they get their tax filings realized they had a policy and didn't know it. Sometimes that's administration issues, sometimes it's broker issues. But right about now is when we see those because that's when the tax filings come due. We're pretty confident in that number and that's a pretty final number for last year. The good news is with all the integrity stuff going on, you're going to see a lot less of that going forward.

And then lastly, as Joe mentioned on the new store impact of Connecticut, that ran in the high 80s initially. We'll pull that down quick with the Molina playbook, but there's a little bit of noise in there that certainly pulls our reported MCR up. Roll those together, that's the 400 bps we talked about.

And the next question comes from Andrew Mock with Barclays. Please go ahead.

Hi, good morning. In the prepared remarks, you called out higher assumptions for both rates and cost trends. Cost trend, it sounds like the rates is on the Medicaid side, sounds like the cost trend is on the ACA side. Do I have that right? And what exactly are you seeing on each of those items that is informing that updated assumption?

Andrew, I'll give you a high level answer then kick it to Mark. I want to be very clear on what we forecasted for the Medicaid business. We received rate updates in the first quarter of '1 hundred and '50 million dollars which equates to 50 basis points on a full year basis. Those will nearly entirely impact Qs two, '3, and '4, and did not have an impact in Q1. So states are obviously recognizing certain cost pressures and updating rates both on cycle and off cycle to compensate for it.

The only reason we increased our trend estimate for the year is at this early stage in the year, reflecting appropriate conservatism, we were not going to improve our Medicaid MCR by 50 basis points at this early stage. So rather than let those rate increases drop through to our guidance, we offset them with a topside adjustment, if you want to call it, to medical cost trend until we see more in the second quarter. So still holding SERV on our 89.9% MCR estimate in Medicaid for the year, but the rates are moving in the right direction. Mark, anything to add?

That's exactly right, Joe. So on a full year basis, Medicaid guidance unchanged at 89.9%. The only thing that's different is our rate assumption is now 5% versus 4% for the full year. And our trend assumption is 5% versus 4.5% for the full year. And again, this is all a function of the known rates we've received going forward.

Got it. Okay. So it sounds like your forward expectations on forward rates has remained unchanged. Is that right?

No, our forward rates are slightly better. So we're raising our full year guidance from 4.5% to 5%.

Right. But that's for rates you've already received and have visibility into. So are the forward rate expectations also higher? The ones that haven't been finalized?

We rates on 85% of our when we gave initial guidance, we knew about rates on about 75% of our revenue, that's now 85%. So yes, there is an estimate in for the September and October rate adjustments that we still have in at a very modest level. So the 5% annual rate increase includes 85% known rates for the year.

Got it. Understood. And you called out seasonal illness in Medicaid, which sounds like flu. Can you tell us the impact that that had on the quarter? Thanks.

Yes. We've sort of moved to the ILI definition that a lot of people have, which is largely flu at this point. We've not really given a normalized number, but I think the more helpful thing for you is we probably ran 10,000,000 to $15,000,000 hot versus what we might call normal. But again, we had that in our guidance. So that really wasn't a surprise to us.

And your next question will be from Josh Raskin with Nephron Research. Please go ahead.

I just want to ask on the exchanges. So just taking a step back, can you help us understand where the marketplace fits in your long term strategies? I know you went through this at the Investor Day, but are there synergies or other with the other two segments or value comes beyond the gross margin contribution? And I understand medical margin dollars were actually up 20% in 1Q. But is there a desire to sort of bid to think differently about the annual volatility in that book at some point?

Josh, as we said at Investor Day, the product line is completely synergistic with our pure play government sponsored managed care theme to our strategy. As people income up and down from Medicaid into Medicaid expansion, into highly subsidized marketplace, people are moving in and out of life circumstances often, frequently, and having a product where we can capture the member for their lifetime, or as long as they're in government assistance across a broad range of products, is totally synergistic. In fact, when they turn 65, which 50,000 members of ours do every single year, we have a DSNP offering that captures the agent. So very, very synergistic and a attractive contributor to the profile of the business. We were earning nearly double digit pre tax margins in the last two prior years.

We consciously invested that excess margin in membership growth, while still targeting mid single digit pre tax margins. We will grow the business at a rate that allows us to hit mid single digit pre tax margins for the reasons you articulated, that it can be volatile. When you bring on new membership, not knowing their cost profile and not having the benefit of risk adjustment means there is a cost to growth and we want to manage that volatility. Mark, anything to add?

No, I think that's well summarized. Joe, you've sometimes referred to it as a residual market because when other things in the economy go up and down, it sort of captures the excess. Therefore, is more volatility, Josh. And what we've always been very clear about is it's a relatively small part of our portfolio. We will price for margin and let the volume fall where it does.

And your next question will come from A. J. Rice with UBS. Please go ahead.

Hi, everybody. Thanks for the question. When you step back, you mentioned a nod to the Washington backdrop of all this chatter about Medicaid cuts, adjustments, whatever. I wonder, is that are you seeing that in any way impact the discussions with states around rate updates or RFP processes? Or is what's going on in Washington and any uncertainty that creates having any impact on any of any of that?

No, AJ, I would say not. The rate discussions are pure, you know, actuary to actuary, looking at the actuarial data. And the real positive news about rates is the cost pressure are coming from cost categories that are very discrete and prominent in the rate models. LTSS rated separately, behavioral usually viewed separately, as well as high cost drugs, including GLP-1s. So the cost pressures that the industry is experiencing are very highly profiled in the rate development environment.

That is, it's a debate about cost trends, it's a debate about what's a credible baseline and a trend off that baseline purely has nothing to do with the Washington debate about how far to pull back Medicaid. Same thing with the RFP cycle. The RFP cycle right now is actually at a low point, it was at a high point in the last two years, where we did really, really well as advertised. It is $50,000,000,000 from 2025 to 2028 in total contract value. We have our eyes on a couple of very attractive opportunities.

And the reprocurement cycle is actually at a low point as well, where we don't have a lot of reprocurements coming up in the next twenty four months. But no, the dialogue in Washington is not causing any state to really rethink either the rate development process or when they reprocure their program.

And your next question comes from Justin Lake with Wolfe Research. Please go ahead.

Thanks. Good morning. Question on effectuation rates, Joe. Can you remind us what you're seeing there? And then can you give us a ballpark of what the MLR looks like for those members versus the overall book?

Sure, I'll give you a high level answer and then hand it to Mark. But we've had a very successful open enrollment period in Marketplace, a very successful special enrollment period early on, where we're sitting here with 660,000 members having ended last year at 400. Our effectuation rates seem to be better or higher than many of our competitors for a variety of reasons. Mark, do you want to elaborate?

Yes. Good morning, Justin. We are actually seeing pretty good effectuation rates and you might be comparing that to what others have said in the market and I can't really talk to their results. But I think we mentioned last time around, we're either number one or number two in about 50% of our footprint. And part of the fluctuation is people rolling into the new cycle and seeing that their payments are maybe different than they were last year, which is a function of pricing.

So some of the folks that might be losing might be at different points on the pricing scale. And I think people through effectuation are staying with Molina or in the case of SEP coming to Molina. So we're seeing good results on both SEP and effectuation. Now on the MLR, it's really too soon this early in the year to get a handle on that because 50% of the book is new, which is not an unusual phenomenon. But we'll have to see how that develops.

And if you ask that question in the second quarter, I'll be able to give you a pretty specific view.

And your next question comes from John Stansell with JPMorgan. Please go ahead.

Great. Thanks for taking my question. Last quarter, you spoke to G and A being a little bit more front loaded as you take on the IT costs for the $1 of implementation cost in $25 I think G and A came in nicely in the quarter. I guess, how are we thinking about progression for G and A this year? And how we get to kind of 10 basis points lower than your initial expectation?

John, the G and A story is a very positive one for us. We focus on it with the same discipline and rigor that we focus on every dollar of medical costs. We've broken through the 7% barrier, we've broken through that. And I'm going to talk on a mix equivalent basis, because obviously mix matters to the G and A ratio, but on a mix equivalent basis, we're comfortably in the high sixes. We think over time, as we grow to the $55,000,000,000 of 2027 revenue target, with our discipline over fixed cost leverage, we can move that down on a mix equivalent basis into the mid sixes, perhaps even the low sixes.

It's a very positive part of the story. That's either going to improve margins over time in our investment thesis or serve to act as a hedge to any MCR pressure we might see over the long term. Mark, on the short term?

Yes, John, if you're looking to model the rest of the year, expect a pretty flat G and A trajectory across the year. We had a 6.8% year in the first quarter. We'll have a 6.9% in our guidance, which implies pretty flat across the full year. What's maybe driving that? We talked about more of the implementation costs upfront in the year.

And that's true. It's a little more front end loaded. But the back end loaded part is always some of the marketing costs around the OEP within Medicare and marketplace that usually drive up G and A. So you've got some different things going on, but I think a pretty flat G and A story through the year.

And your next question comes from Sarah James with Cantor Fitzgerald. Please go ahead.

Thank you. One clarification and then a Hicks question. So just to clarify, when you moved up the Medicaid cost trend 50 basis points, was that pure conservatism or did you see trend data above your prior expectations? And then on exchanges, do you think that the pricing and benefit design changes or the new member mix could change your MLR seasonality on the Hicks business?

Sarah, you heard my prepared remarks correctly. In the Medicaid business, we absolutely received rate updates of a hundred and $50,000,000, which caused us to increase our full year rate update from previous guidance of 4.5% to 5%. As I said, in our member month mix, 85% of rates on our member months are known at this point in time, only 15% is an estimate. Those rate updates will impact quarters two, three, and '4. Having known that, we then said, do we let that drop through to our guidance and drop our NCR guidance by 50 basis points?

At this early stage and in this environment, we decided not to. We saw no empirical evidence in the first quarter, which caused us to increase trend. The increase in trend from 4.5 to five to be commensurate with rates was entirely due to early in the year conservatism. We'd like to see how the second quarter experience emerges before making a final call on updating the Medicaid MCR for the full year. Your second question on HITS, can you repeat it please?

I'll take that one. Hey, Sarah, on the full year trajectory of marketplace MLR, we're a little flatter than normal, this year or at least in prior years. First of all, we've got more new membership in SEP this year. So we're a little more conservative in our initial picks. But the other thing is you'll see Connecticut improving through the year as new stores typically do.

And then lastly, we've got a lower bronze mix this year and bronze tends to be a much more seasonal product. So a little bit flatter on the trajectory if you're modeling it.

And your next question will come from Joanna Gajuk with Bank of America. Please go ahead.

Hey, good morning. Thanks so much for taking the question. So if I may, given the discussions around trend by product, I don't think I heard you talk about MA. I know you said that in the quarter, it sounds like MLR was in line with expectations. So can you talk about anything that's maybe happening in your Medicare Advantage book?

And are you still expecting same trend for the year? I think you had said on the last quarter an increase of 2.7% for the year. Thank you.

Yes, I'll take that one. So, so far Medicare playing out much like we expected. We had guided to an 89 and we're still quite confident in an 89. You're right in remembering the build trend was about 2.7 in our original number and rates were just a little bit less than that. So far, I'm seeing utilization V28, all of those matters as well as the Part D under the IRA, all of those matters pretty much coming in as we anticipated.

And remember, that's a much smaller part of our book.

And your next question will come from Ryan Langston with TD Cowen. Please go ahead.

Thanks. I want to go back to A. I guess on M and A with sort of the backdrop uncertainty reconciliation enhanced subsidies etcetera. I guess is that impacting the willingness of potential M and A targets to engage on a potential deal or is it having any impact on the potential multiples just given we don't know where everything's going to shake out? Thanks.

On the M and A front, the pipeline is still replete with opportunities. Obviously, the last one we announced was the Connecticut acquisition. But the pipeline is full. Our M and A team is actively engaged in analyzing core products, core markets, and attractive prices. The businesses are underperforming, and in this environment, as you know, performance is a challenge in this environment.

Some of these smaller single state, single geography companies are struggling. So no, I would say that it's not casting a poll over the M and A activity. In fact, it might even be increasing some of the flow as some of these single state operators have seen how difficult it is to run a business. We have the benefit of 22 state diversification. Single state, single geography companies don't.

So I would say it's almost quite the opposite. The pipeline is full of opportunities, and we hope to fulfill the commitment we've made that one third of our forward growth rate, as we said at Investor Day, is likely coming from M and A, bearing in mind that we're already at our $52,000,000,000 estimate for 2027, which is the low end of our range. I've got eighteen to twenty four months to fill that other $3,000,000,000 and while nothing's a layup in this business, highly confident we're going to do it.

And your next question will come from Lance Wilkes with Bernstein. Please go ahead.

Great, thanks. Can you talk a little bit about network contracting? Interested in how supplemental payments have been impacting hospitals and whether that's impacted kind of the growth in access with hospitals in your network? And then also, what are you seeing as far as and what are you doing in the form of value based care contracting? Do you see any subcomponents of that?

Do you feel you're going to need to own or partner? And maybe as you're doing that, if you can just kind of clarify on utilization, if there are any unusual puts and takes between categories of like hospital, behavioral drugs, etcetera. Thanks.

Lance, let me take the second part of your question first on value based care and value based contracting. As you know, in the past five years, most of the activity on VBC has been aimed at Medicare Advantage. That's where the lives are, that's where the premium was, and that's where a lot of the activity. It is coming to Medicaid, it is coming to Medicaid more slowly. There are regulatory definitions of how much of your medical cost needs to go through a VBC arrangement.

We are fully compliant with the minimum requirements. Now it's about can you manage your cost structure and risk adjustment based on your relationships. We're getting there. We have a national networking unit has a VBC arm. They are actively engaged in working with our major provider partners where we have membership density to work on value based care arrangements.

Again, over the next two or three years, we will increase our penetration. Right now, we are fully compliant with the regulatory rules. On your other question about supplemental payments, let me kick it to Mark and let him take that one.

Molina Healthcare (MOH) Q1 2025 Earnings Call Transcript

Company Participants